FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer’s Disease Study, Streamlining Development Pathway
07 janv. 2025 08h00 HE
|
Annovis Bio, Inc.
MALVERN, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies...
Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation
30 déc. 2024 07h00 HE
|
Axsome Therapeutics, Inc.
ACCORD-2 Phase 3 trial in Alzheimer’s disease agitation achieves primary endpoint compared to placebo (p=0.001, time to relapse) ACCORD-2 Phase 3 trial achieves key secondary endpoint compared to...
Longeveron to Present at Biotech Showcase 2025
18 déc. 2024 09h10 HE
|
Longeveron
Longeveron Chief Executive Officer Wa’el Hashad will give a corporate presentation at Biotech Showcase, being held January 13-15, 2025.
Vaccinex Announces Receipt of Delisting Notification from Nasdaq
17 déc. 2024 09h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to...
Global Alzheimer’s Platform Foundation Announces Strategic Collaboration with Eli Lilly and Company for the Transformative Bio-Hermes-002 Study
09 déc. 2024 10h00 HE
|
Global Alzheimer’s Platform Foundation®
Washington D.C., Dec. 09, 2024 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Eli Lilly and Company (Lilly) to the Bio-Hermes-002 study. This...
Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024
02 déc. 2024 09h05 HE
|
Longeveron
Longeveron will participate in the Emerging Growth Virtual Conference with company presentation December 5th at 12:00pm ET.
Annovis to Host Year-End Investor Webcast on December 11, 2024
25 nov. 2024 08h00 HE
|
Annovis Bio, Inc.
MALVERN, Pa., Nov. 25, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, is pleased...
Longeveron® Announces Third Quarter 2024 Financial Results and Provides Business Update
12 nov. 2024 16h05 HE
|
Longeveron
Longeveron reports 3Q24 financial results. Pivotal Phase 2b clinical trial in HLHS achieves 80% enrollment. Positive Phase 2 data for Alzheimer's disease.
Bridging Health Equity Gaps: Creyos Launches an Even More Accessible Patient Experience
05 nov. 2024 08h00 HE
|
Creyos
Toronto, Canada, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Creyos, a leader in cognitive and behavioral health assessment, has announced significant enhancements to its online platform to improve...
Longeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)
29 oct. 2024 10h00 HE
|
Longeveron
Longeveron presents clinical data for stem cell therapy in Alzheimer's disease. Findings offer potential mechanistic and clinical insights.